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Abstract
Background: Infection rates for many infectious diseases have declined over the past
century. This has created a cohort effect, whereby older individuals experienced a higher
infection rate in their past than younger individuals do now. As a result, age-stratified
seroprevalence profiles often differ from what would be expected from constant infection
rates.
Methods: Here, we account for the cohort effect by fitting an age-structured
compartmental model with declining transmission rates to Hepatitis A seroprevalence data
for Canadian-born individuals. We compare the predicted impact of universal vaccination
with and without including the cohort effect in the dynamic model.
Results: We find that Hepatitis A transmissibility has declined by a factor of 2.8 since the
early twentieth century. When the cohort effect is not included in the model, incidence and
mortality both with and without vaccination are significantly over-predicted. Incidence
(respectively mortality) over a 20 year period of universal vaccination is 34% (respectively
90%) higher than if the cohort effect is included. The percentage reduction in incidence and
mortality due to vaccination are also over-predicted when the cohort effect is not included.
Similar effects are likely for many other infectious diseases where infection rates have
declined significantly over past decades and where immunity is lifelong.
Conclusion: Failure to account for cohort effects has implications for interpreting
seroprevalence data and predicting the impact of vaccination programmes with dynamic
models. Cohort effects should be included in dynamic modelling studies whenever
applicable.
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Hepatitis A
Hepatitis A virus (HAV) is endemic in most countries [1-
4], although infection rates continue to decline as hygiene
and sanitation improve [5]. Infection is often subclinical
in children but the majority of infected adults develop
clinical symptoms, and often do not seek medical atten-
tion [5,6]. The severity of HAV infection increases with age
and is particularly severe for those with underlying
chronic liver disease [7-10]. The rate of mortality attribut-
able to HAV increases by age from a 0.2% in symptomatic
young adults to 3.9% in symptomatic adults over the age
of 80 [11]. The clinical illness usually lasts 4 weeks and
symptoms include nausea, loss of appetite, fatigue, fever,
abdominal pain and jaundice [6].
HAV is transmitted by the fecal-oral route. Chronic infec-
tion does not occur [12], and immunity appears to be life-
long [7]. Traditionally, children have played a prominent
role in transmission due to poor hygiene and the high
probability of subclinical infection [13]. The reported
incidence in Canada from 1980–1994 was twice as high
in the 5–9 age groups as in other age groups [14], and
once the reduced probablility of clinical infection in chil-
dren is taken into account [6,15-19], true infection rates in
children are seen to be significantly higher than in adoles-
cents and adults. Approximately 25–50% of clinical cases
have unidentified risk factors [20]. Many of these may
have been contacts of children with subclinical infection.
In Canada, HAV is not endemic and transmission is pri-
marily person-to-person [5] with rare foodborne out-
breaks [21]. Risk factors for contracting HAV are often
unidentified [20,21], but known risk factors include
membership in high risk groups (including men who
have sex with men, injection drug users and the home-
less), low socioeconomic conditions [22], membership in
socially-contained religious communities [23-25], and
travel to endemic areas [26,27]. The latter is a particularly
significant risk factor in Canada. Secondary infections
from index cases infected abroad [25,28,29] and intra-
household transmission [30] are also significant. From
1980 to 1994 (the year of vaccine licensure in Canada),
the average incidence of reported cases was 6.3 per
100,000 per year [14] (Figure 1).
Case reports reveal when clinical infections occur, but
they do not account for subclinical infection and under-
reporting [1,5]. By comparison, seroprevalence data can
accurately determine what proportion of individuals have
been infected by a given time, but cannot say when the
infection occurred. Estimates of true infection rates usu-
ally rely upon seroprevalence surveys and/or case report-
ing data. Catalytic modelling uses integral equations to
reconcile case reporting and seroprevalence data via statis-
tical regression, yielding estimates of the true infection
rates and how they have evolved over time. According to
estimates from catalytic modelling, infections are under-
reported by a factor of 10 in the United States [31,32].
Cohort effects
To date, there is no representative national seroprevalence
survey for HAV in Canada. However, an approximate age-
stratified seroprevalence profile has recently been synthe-
sized from various independent surveys by the method of
systematic review [33]. The resulting profile is both rea-
sonable and consistent with the profile observed in the
NHANES (National Health and Nutrition Examination
Survey) II and III surveys in the United States [31]. The
observed seroprevalence in Canada and the United States
is too low in the youngest age classes and too high in older
age classes to be consistent with the assumption of con-
stant infection rates over time. Instead, it is necessary to
posit that infection rates were higher in past decades due
to a lower level of sanitation and hygiene [34]. This is usu-
ally described as a cohort effect [5]. Cohort effects have
also been observed in other populations [34,35].
The presence of cohort effects in seroprevalence data is
widely recognized. However it is difficult to characterize
cohort effects without a mathematical model since the
two dimensions involved – age class and calendar year –
are easily confounded. Figure 2 illustrates how two
cohorts born at different times experience different infec-
tion rate histories, when infection rates decline over time.
The expected seroprevalence for a given cohort can be
thought of as an integration of the infection rate history
over the cohort's life history path in Figure 2. When infec-
tion rates have been constant over time, age-stratified
Hepatitis A incidence in Canada (number of cases per 100,000 per year), 1978–2003Figure 1
Hepatitis A incidence in Canada (number of cases per 
100,000 per year), 1978–2003.Page 2 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:174 http://www.biomedcentral.com/1471-2334/6/174seroprevalence profiles have a convex shape, increasingly
monotonically with age but with progressively smaller
increases for increasing age. However, when a strong
cohort effect is present due to rapidly declining infection
rates, an S-shaped age-stratified seroprevalence profile
should be observed.
Goals of study
Few dynamic models have been developed for HAV, com-
pared to other common infectious diseases [34,36-38].
Dynamic modelling studies and other studies which esti-
mate infection rates for many diseases often do not take
the cohort effect into account, resulting in inaccurate pre-
dictions. Here we develop and analyze a dynamic model
for Hepatitis A in Canada. Our goal is to quantify how
infection rates have declined over the past century, to
illustrate how dynamic models which include the cohort
effect can reconcile case reporting data and seroprevalence
data, and to illustrate how the predicted impact of vacci-
nation on incidence and mortality varies depending on




We develop an age-structured compartmental model to
study HAV transmission and vaccination in Canada. The
literature on age-structured compartmental models is
well-established and has developed extensively since the
mid-1980s [39]. Such models have long been applied to
infectious diseases where natural immunity is lifelong and
transmission is primarily person-to-person, as is the case
for HAV in Canada. They have been validated against epi-
demiologic data [39-42] and have been used by health
authorities in decision making processes for vacination
policy [43]. Our SEIRV (Susceptible-Exposed-Infectious-
Recovered-Vaccinated) compartmental model allocates
all members of the population into mutually exclusive
compartments according to age class and epidemiologic
status: the number susceptible (Si), exposed (infected but
not yet infectious, Ei), infectious (Ii), recovered (Ri), and
vaccinated (Vi) in each age class i. The age classes are 0–4,
5–9, 10–19, 20–29, 30–39, 40–59 and 60+, chosen to
reflect age categories in available sources of demographic
and epidemiologic data.
Flow rates between compartments are defined by model
parameters. Exposed individuals enter the infectious com-
partment at rate δ, and infectious individuals enter the
recovered compartment at rate γi, thereafter retaining life-
long immunity. Individuals in age class i are vaccinated at
per capita rate gi thereby entering the vaccinated compart-
ment, and vaccinated individuals lose their immunity at
per capita rate f, re-entering the susceptible compartment.
Individuals are born susceptible at rate b, and when a
given birth cohort enters the next highest age class, a pro-
portion di of them die. Maternal immunity is short-lived
and affects relatively few individuals in a non-endemic
country such as Canada, so we do not include it [5]. HAV
in Canada is spread primarily person-to-person [5]. Hence
we do not model foodborne or waterborne outbreaks. The
transmission rates and the model for the cohort effect are
described in the following subsections. The model is
parameterized using data from the clinical literature [44-
50], demographic [51] and travel data [26,52-55], case
reports [14], and seroprevalence suveys [33]. Model equa-
tions appear in Additional File 1 and the parameterization
is described in Additional File 2. A diagram of the model
appears in Figure 3.
Travel transmission rates
Estimates of the proportion of HAV cases attributable to
travel in endemic countries range from 26% to 40%,
depending upon the year and location [26,53-55]. A con-
siderably higher proportion of cases are attributable to
travel in younger age classes than in older age classes [55].
The predicted impact of vaccination, and the fit of the
model to the data, can vary significantly depending on
whether travel-related incidence is accounted for. Here we
include travel-related incidence in our model.
If λi denotes the total infection rate in age class i (the rate
at which a susceptible individual in age class i becomes
Illustration of the cohort effect for an idealized situation of no age dependence in infection ratesFigu e 2
Illustration of the cohort effect for an idealized situa-
tion of no age dependence in infection rates. The top 
arrow represents time evolution in the infection rate on a 
cohort born in 1920 and the bottom arrow represents the 
same for a cohort born in 1970. The infection rate is the rate 
at which a susceptible person becomes infected, and here it 
has been expressed in an idealized unit of measurement.Page 3 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:174 http://www.biomedcentral.com/1471-2334/6/174infected), and if κi denotes the proportion of infections in
age class i attributable to travel in endemic countries, then
clearly τi = κi λi where τi is the travel transmission rate, ie,
the rate at which a susceptible person in age class i
becomes infected due to travel in an endemic country. Let
i be the average travel transmission rate for 1980–1994.
We estimate i from the average force of infection λi from
1980–1994 as estimated by catalytic modelling, and from
average κi values for 1980–1994, estimated from surveys
on HAV risk factors (Additional File 2) [26,53-55].
Domestic transmission rates
Since the contribution to the infection rate from travel-
related transmission is κi λi, the remainder (1 - κi)λi is the
contribution from domestic transmission. The domestic
transmission rate βij is the rate at which a susceptible indi-
vidual of age class i in Canada is infected by infectious
individuals of age class j in Canada. The resulting matrix
of 7 × 7 domestic transmission rates form a WAIFW (Who
Acquires Infection From Whom) matrix. By specifying a
structure for the WAIFW matrix, the average values of λi
and κi for 1980–1994 can be used along with estimated
true incidence Ii and data from seroprevalence surveys
[33] to determine the domestic transmission rates ij for
1980–1994 by solving the equation
 (Additional File 2).
Modelling the cohort effect
We have estimated the average travel transmission rate i
and the average domestic transmission rate ij for the
years 1980–1994. The model could be simulated without
including the cohort effect by assuming constant values βij
= ij and τi = i for all time. To include the cohort effect,
these constant values must be replaced by time-varying
values βi = βi (t) and τi = τi (t).
To a good approximation, the per capita annual volume










Diagram of the SEIRV modelFigure 3
Diagram of the SEIRV model.Page 4 of 10
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regression y = 2.38 × 10-5 t2 + 1.52 × 10-3 t + 2.98 × 10-3 (R2
= 0.98) [52]. Hence, it is possible to estimate a time-vary-
ing travel transmission rate, τi (t), by assuming that τi (t)
increased over the past half century according to the same
quadratic regression, rescaled to match the known average
value i for 1980–1994 (Additional File 2).
Additionally, the domestic transmission rate βi (t) can be
assumed to obey βij (t) = ij F (t) = ij [L + H (1 - tanh(A(t
- T)))], where tanh(t) = (exp(2t) - 1)/(exp(2t) + 1) is the
hyperbolic tangent function. The function F(t) describes a
continuous decline from an upper bound to a lower
bound. The parameter L determines the lower bound
attained for sufficiently large time t, L+H determines the
upper bound attained for sufficiently small t, T deter-
mines the timing of the transition between these upper
and lower bounds, and A controls how abrupt the transi-
tion is.
We estimated L, H, T and A by exploring a plausible region
of LHTA parameter space with fine resolution and mini-
mizing the least-squares error between predicted seroprev-
alence values and the observed values from the 11
seroprevalence surveys for Canadian-born individuals of
distinct age classes and survey years, between 1980 and
1994 [27,33,56-58]. It was assumed that τi = τi (t) as esti-
mated above. With this method we obtained L = 0.73, H
= 0.84, A = 0.038, T = 1960.
A previous study has also captured cohort effects by fitting
a function for declining infection rates to age-stratified
seroprevalence data [34]. The main differences with the
previous study are that the current study includes infec-
tion due to travel in endemic countries and also explores
how including the cohort effect changes the predicted
impact of vaccination.
Uncertainty analysis
To derive uncertainty intervals we applied the Latin hyper-
cube method [59] to those parameters with the least cer-
tain values: the infection rates as estimated from catalytic
modelling (λi), the duration of infectiousness (γi) and the
proportion of travel-related incidence (κi). For each sam-
pled parameter set, the model was fitted as before to the
seroprevalence data to obtain values for L, H, T, and A and
then seroprevalence and incidence were computed.
Details appear in Additional File 3.
Results
Declining transmissibility
If infection rates are assumed to be unchanged over the
past century (ie, constant transmission rates ij and i
are assumed) then the modelled seroprevalence profile
exhibits a large error relative to the observed data from the
11 seroprevalence surveys for Canadian-born individuals
(Table 1) [27,33,56-58]. The predicted seroprevalence is
too large in the youngest age classes and too small in the
oldest age classes. The predicted incidence is significantly
larger than observed incidence for all age classes (Table 2).
By comparison, there is good agreement between fitted
and observed seroprevalence when infection rates βij (t)
and τi (t) evolve over time as described in Methods (Table
1). Accounting for the cohort effect through a declining
transmissibility function explains most of the difference
between fitted and observed seroprevalence (R2 = 0.97).
The remaining discrepancies may partly be due to other
heterogeneities not accounted for, such as outbreaks in
high risk groups during specific periods, or constraints
inherent to the hyperbolic tangent model. The fitted sero-
prevalence remains somewhat high in the younger age
classes and somewhat low in the older age classes. The
agreement between predicted and observed incidence also
improves dramatically once the cohort effect is included
(Table 2). Observed incidence values fall within 96%
uncertainty intervals of the predicted values. A piecewise
exponential function for F(t) yields similar results.
Figure 4 illustrates the time evolution of transmissibility
F(t) over the past century from the fitted model. Transmis-
sibility has dropped by a factor of 2.8 since the 1920s. The
period of most rapid change was from 1950 to 1970,
which is consistent with an era of rapid improvements in
hygiene and sanitation in Canada, due ultimately to post-
war economic growth.
Universal vaccination
Here we compare the predicted effects of universal vacci-
nation in Canada over 20-year and 50-year periods start-
ing in 2006, with and without inclusion of the cohort
effect in the dynamic model. For the case of constant
transmissibility (cohort effect is not included), transmis-
sion rates in the vaccine era are assumed to be constant (βij
= ij τi = i, as in Methods). For the case of declining
transmissibility (cohort effect is included), transmission
rates in the vaccine era are given by βij = βij (t), τi = τi (t),
the same functions used to fit the model to the seropreva-
lence surveys but extrapolated to the vaccine era. The
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sion rate until the reported age-specific incidence from
1995–2005 is recovered, and thereafter the targeted policy
is discontinued. Other parameters are unchanged from
1980–1994 values. Vaccination is applied to 4-year-olds
and calls for two doses of vaccine with 70% compliance
and 97% vaccine efficacy [49,50]. Vaccination occurs at
age 4 because this would allow Hepatitis A vaccination to
be efficiently scheduled along with other currently-
administered vaccines in Canada. The assumed rate of
waning of vaccine-derived immunity was 1.65% per year
[47], which is a conservative assumption since cell-medi-
ated immunity may actually result in lifetime protection.
Over both 20- and 50-year periods, failure to include the
cohort effect over-estimates incidence and mortality, both
with and without vaccination (Tables 3, 4). If the cohort
effect is not included, the average reported incidence over
20 years is predicted to be 7.8 per 100,000 per year. If the
cohort effect is included, it is 5.8 per 100,000 per year.
Likewise, the cumulative number of deaths attributable to
HAV over 20 years is predicted to be 262 instead of 138.
Hence, from the perspective of absolute incidence in the
vaccine era, not including the cohort effect will under-esti-
mate the effectiveness of vaccination.
On the other hand, from the perspective of percentage
reductions in incidence and mortality brought on by vac-
cination, the effectiveness of vaccination can be signifi-
cantly over-estimated if the cohort effect is not included.
In this case the percentage reduction in incidence (respec-
tively mortality) due to vaccination is 43% (respectively
Table 2: Average observed incidence of reported cases (per 100,000 per year) versus predicted incidence of reported cases for the case 
of constant domestic (βij = ij) and travel (τi = i) transmission rates, and for the case of time-varying domestic (βij = βij (t)) and travel 
(τi = τi (t)) transmission rates, from 1980–1994.
Average incidence of reported cases, 1980–1994
Age Class Observed Predicted, without cohort effect Predicted, with cohort effect
0–4 6.8 10.3 (1.4, 19.2) 7.4 (5.7, 11.6)
5–9 17.0 21.8 (3.3, 40.3) 15.7 (11.9, 23.9)
10–19 7.8 13.8 (4.6, 23.0) 9.6 (7.4, 12.1)
20–29 9.4 14.8 (2.8, 26.8) 9.8 (7.3, 13.8)
30–39 7.2 16.1 (1.4, 30.8) 9.4 (7.0, 13.4)
40–59 3.7 11.3 (1.9, 20.7) 4.0 (3.1, 5.3)
60+ 1.8 12.2 (0.8, 23.6) 2.2 (1.6, 3.2)
All ages 6.5 13.8 (2.2, 25.4) 7.5 (5.2, 10.7)
The quantities in brackets represent 96% uncertainty intervals (see Methods).
β τ
Table 1: Observed seroprevalence versus fitted seroprevalence for the the case of constant domestic (βij = ij) and travel (τi = i) 
transmission rates, and for the case of time-varying domestic (βij = βij (t)) and travel (τi = τi (t)) transmission rates.
Seroprevalence
Age class, year, survey Observed Fitted, without cohort effect Fitted, with cohort effect
0–4, 1981, Ref. 58 0.0024 0.014 0.009
5–9, 1981, Ref. 58 0.0024 0.047 0.030
10–19, 1988, Ref. 59 0.0063 0.068 0.046
10–19, 1995, Ref. 27 0.0299 0.068 0.048
10–19, 1981, Ref. 57 0.0632 0.068 0.049
20–29, 1988, Ref. 59 0.103 0.082 0.064
20–29, 1980, Ref. 57 0.114 0.082 0.129
30–39, 1988, Ref. 59 0.287 0.097 0.171
40–59, 1980, Ref. 57 0.599 0.115 0.618
40–59, 1988, Ref. 59 0.550 0.115 0.491
60+, 1988, Ref. 59 0.820 0.137 0.745
The seroprevalence values listed under "Observed", "Without cohort effect" (fitted model, constant case) and "With cohort effect" (fitted model, 
time-varying case) are for the timepoints specified in the first column.
β τPage 6 of 10
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included. These figures are 23% (respectively 73%) when
the cohort effect is included. Patterns are similar over 50
years. The drop in mortality brought on by vaccination is
largest in the oldest age classes since older individuals
tend to be at a higher risk for mortality attributable to
HAV.
The absolute and relative differences between incidence
and mortality with and without vaccination, over 20-year
and 50-year periods, are also larger when the cohort effect
is not included.
We note that the average annual reported cases and deaths
are somewhat higher over the 50-year period than the 20-
year period (Tables 3 and 4). This occurs because the
travel transmission rate after 2006 continues to climb
according to our fitted function τi = τi (t) that reflects long-
term historical trends in travel. Hence, the number of
individuals infected through travel to HAV-endemic
countries continues to rise, while the fall in the domestic
transmission rate βij = βij (t) after 2006 is much more mod-
erate. Another possible reason for this effect is that a
decrease in incidence in the younger, recently-vaccinated
age classes is offset by an increase in incidence in the older
age classes, who are increasingly susceptible as more time
passes since the cessation of the (all-ages) targeted policy
in 2006. We have assumed that vaccine-derived immunity
wanes, and so not all individuals vaccinated as children
retain their immunity when older. Older age classes also
experience higher rates of mortality attributable to HAV,
so the net number of deaths can increase over time.
Discussion
These results indicate that the presence of a cohort effect
can significantly alter the impact of vaccination. The
implicit assumption that infection rates have always been
constant is frequently made in modelling studies, but it is
incorrect for many common infectious diseases. Failure to
include the cohort effect overestimates incidence and
mortality both before and after introduction of universal
vaccination, as well as the percentage reduction achieved
by universal vaccination.
Cohort effects are not immediately obvious in case report-
ing data or seroprevalence survey data. In seroprevalence
data, it is often difficult to disentangle the two dimensions
– calendar year and age – that are present in any set of
seroprevalence surveys (Figure 2). In case reporting data,
there is not a simple one-to-one relationship between
Table 3: Predicted annual incidence of reported cases, with and without including the cohort effect in the dynamic model.
Average annual reported incidence (cases per 100,000 per year)
Over 20 years (2006–2025) Over 50 years (2006–2055)
Without cohort effect With cohort effect Without cohort effect With cohort effect
Age Class Vaccination No vaccination Vaccination No vaccination Vaccination No vaccination Vaccination No vaccination
0–4 6.4 10.3 5.6 7.9 6.2 10.3 5.4 7.6
5–9 7.0 21.8 6.2 16.9 5.8 21.8 5.1 16.3
10–19 6.9 13.8 5.9 10.3 5.0 13.8 4.3 10.0
20–29 9.4 14.8 7.8 10.6 6.6 14.8 5.5 10.2
30–39 10.1 16.1 8.3 11.3 8.1 16.1 6.5 10.8
40–59 7.0 11.3 4.8 6.7 6.3 11.3 4.7 7.0
60+ 7.3 12.2 2.7 3.9 6.8 12.2 3.8 5.7
All Ages 7.8 13.8 5.8 9.0 6.4 13.8 5.0 9.1
HAV transmissibility over time, as determined from fitting the dyn mic model to s opr valence dataFigure 4
HAV transmissibility over time, as determined from 
fitting the dynamic model to seroprevalence data. 
The vertical axis shows the function F(t) which describes 
time evolution of transmissibility.Page 7 of 10
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cases where the probability of clinically apparent infec-
tion varies with age. In some situations, a rise in reported
incidence may actually signal reduced infection rates in
the general population or in certain age cohorts. This may
have happened in Canada in the last decades of the twen-
tieth century. Reported incidence in Hepatitis A in Canada
exhibits an increasing trend between the years of 1980
and 1996 (linear regression: y = 0.21x + 4.61, R2 = 0.24;
the R2 value is low because of the recurrent outbreaks).
The dynamic model during this time predicts an increase
in reported incidence (linear regression: y = 0.18x + 5.92,
R2 = 0.99) while simultaneously predicting a decrease in
true (actual) incidence due to a declining transmission
rate (Figure 4). This occurs because declining transmissi-
bility yields a decrease in the infection rates and hence an
increase in the mean age at infection. Because of age
dependence in the probability of clinical infection, this
translates into more reported HAV infections. However, in
other situations, variation in reported incidence over time
may also be due to changing case reporting methods.
Because of such subtleties, dynamic modelling provides a
rigorous and transparent framework for the interpretation
and synthesis of seroprevalence and case reporting, and
especially the clarification of cohort effects (eg, Figure 4).
Modelling is valuable not only for predicting the impact
of proposed policies but also for understanding and inter-
preting epidemiologic data. When developing dynamic
models of disease transmission and vaccination, seroprev-
alence data should be interpreted carefully and incorpo-
rated into model parameterization whenever possible.
In our parameterization, some of the seroprevalence sur-
vey data were used twice. Firstly, they were used in the cat-
alytic modelling to determine the proportion of
seropositive individuals and hence the infection rates.
Secondly, they were used to fit the function F(t) for declin-
ing transmissibility. This two-step approach may intro-
duce bias, since it assumes transmissibility has declined in
each age class in the same way over the past century. An
alternative approach might have been to fit functions for
declining transmissibility for each age class separately.
However, this would mean estimating 10 parameters
using 11 data points, which constitutes a poorly deter-
mined problem. In situations where more data points are
available, this latter approach could be desirable.
In Canada, Hepatitis A transmission is primarily person-
to-person. For other countries where environmental trans-
mission is a significant source of Hepatitis A infection, the
model would have to be modified to take environmental
transmission into account [60].
Although this study addresses HAV specifically, the results
should apply to any infectious disease in which there is
lifelong immunity, person-to-person transmission, and
where infection rates have changed significantly in past
decades. Many pediatric infectious diseases fall into this
category, with one difference being that disease severity
declines with age instead of increasing, as with HAV.
Hence, for many dynamic modelling studies, it may be
necessary to account for cohort effects.
Conclusion
Failure to account for cohort effects has implications for
interpreting seroprevalence survey data and parameteriz-
ing dynamic models. Moreover, for Hepatitis A, the pre-
dicted impact of universal vaccination can vary widely
depending on whether the cohort effect is included in the
Table 4: Predicted cumulative number of deaths attributable to HAV, with and without including the cohort effect in the dynamic 
model.
Cumulative number of deaths
Over 20 years (2006–2025) Over 50 years (2006–2055)
Without cohort effect With cohort effect Without cohort effect With cohort effect
Age Class Vaccination No vaccination Vaccination No vaccination Vaccination No vaccination Vaccination No vaccination
0–4 7.6 12.3 6.8 9.5 18.5 30.8 16.2 22.9
5–9 5.0 15.7 4.4 12.1 10.5 39.2 9.2 29.3
10–19 9.9 19.9 8.5 14.9 17.9 49.6 15.5 36.0
20–29 13.5 21.3 11.3 15.3 23.7 53.2 19.7 36.6
30–39 17.0 27.1 13.9 19.0 33.9 67.7 27.5 45.5
40–59 48.9 79.2 33.6 46.8 109.7 198.0 81.7 122.7
60+ 159.6 265.6 59.3 85.6 367.7 664.0 205.5 311.4
All Ages 261.6 441.0 137.9 203.2 581.8 1102.5 375.3 604.5Page 8 of 10
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BMC Infectious Diseases 2006, 6:174 http://www.biomedcentral.com/1471-2334/6/174dynamic model. This is likely to be true for any infectious
disease with lifelong immunity in populations with pro-
nounced cohort effects. Hence, cohort effects should be
accounted for in dynamic modelling studies whenever
applicable.
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